GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,538.00
Bid: 12,536.00
Ask: 12,542.00
Change: 22.00 (0.18%)
Spread: 6.00 (0.048%)
Open: 12,566.00
High: 12,572.00
Low: 12,526.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

11 Apr 2024 17:30

RNS Number : 3420K
AstraZeneca PLC
11 April 2024
 

11 April 2024 1730 BST

 

Results of Annual General Meeting held on 11 April 2024

 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

Resolution

Votes for

% of votes cast

Votes against

% of votes cast

Votes cast in total

Total votes cast as a % of issued share capital

Votes withheld

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023

1,205,690,871

99.88

1,470,816

0.12

1,207,161,687

77.87%

9,700,968

2

To confirm dividends

1,215,177,590

99.94

790,189

0.06

1,215,967,779

78.44%

894,978

3

To reappoint PricewaterhouseCoopers LLP as Auditor

1,208,377,872

99.36

7,843,545

0.64

1,216,221,417

78.45%

642,048

4

To authorise the Directors to agree the remuneration of the Auditor

1,215,717,786

99.98

279,816

0.02

1,215,997,602

78.44%

722,222

5a

To re-elect Michel Demaré as a Director

1,197,325,871

98.49

18,416,788

1.51

1,215,742,659

78.42%

1,120,559

5b

To re-elect Pascal Soriot as a Director

1,206,729,787

99.26

9,036,742

0.74

1,215,766,529

78.42%

1,098,706

5c

To re-elect Aradhana Sarin as a Director

1,212,225,383

99.71

3,509,122

0.29

1,215,734,505

78.42%

1,129,532

5d

To re-elect Philip Broadley as a Director

1,197,937,103

98.54

17,773,671

1.46

1,215,710,774

78.42%

1,153,360

5e

To re-elect Euan Ashley as a Director

1,213,332,278

99.80

2,375,199

0.20

1,215,707,477

78.42%

1,156,567

5f

To re-elect Deborah DiSanzo as a Director

1,215,396,504

99.97

318,525

0.03

1,215,715,029

78.42%

1,149,106

5g

To re-elect Diana Layfield as a Director

1,215,424,019

99.98

292,514

0.02

1,215,716,533

78.42%

1,147,602

5h

To elect Anna Manz as a Director

1,215,297,866

99.97

417,067

0.03

1,215,714,933

78.42%

1,149,091

5i

To re-elect Sheri McCoy as a Director

1,158,846,767

95.32

56,874,293

4.68

1,215,721,060

78.42%

1,142,920

5j

To re-elect Tony Mok as a Director

1,215,346,936

99.97

346,157

0.03

1,215,693,093

78.42%

1,170,931

5k

To re-elect Nazneen Rahman as a Director

1,191,449,316

98.59

16,988,178

1.41

1,208,437,494

77.95%

8,426,242

5l

To re-elect Andreas Rummelt as a Director

1,215,395,253

99.97

314,359

0.03

1,215,709,612

78.42%

1,154,412

5m

To re-elect Marcus Wallenberg as a Director

947,479,100

77.93

268,252,536

22.07

1,215,731,636

78.42%

1,132,416

6

To approve the Annual Report on Remuneration for the year ended 31 December 2023

1,158,470,360

95.32

56,835,406

4.68

1,215,305,766

78.40%

1,558,941

7

To approve the Directors' Remuneration Policy

 

761,702,826

64.43

420,514,520

35.57

1,182,217,346

76.26%

34,645,873

8

To approve amendments to the AstraZeneca Performance Share Plan 2020

 

769,577,451

65.34

408,204,003

34.66

1,177,781,454

75.97%

39,083,170

9

To authorise limited political donations

1,184,223,861

98.00

24,219,787

2.00

1,208,443,648

77.95%

8,278,265

10

To authorise the Directors to allot shares

1,129,625,915

92.94

85,836,406

7.06

1,215,462,321

78.41%

1,259,562

11

To authorise the Directors to disapply pre-emption rights

1,044,559,011

85.95

170,708,848

14.05

1,215,267,859

78.39%

1,454,048

12

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

997,629,834

82.33

214,143,713

17.67

1,211,773,547

78.17%

4,948,031

13

To authorise the Company to purchase its own shares

1,205,828,976

99.23

9,306,860

0.77

1,215,135,836

78.38%

1,585,923

14

To reduce the notice period for general meetings

1,131,157,449

93.07

84,269,754

6.93

1,215,427,203

78.40%

1,294,801

 

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 Statement in connection with resolutions 5m, 7 and 8

AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.

We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.

Issued capital

As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGPUUPCUPCGQG
Date   Source Headline
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration
1st May 20183:00 pmRNSTotal Voting Rights
27th Apr 201812:30 pmRNSAZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 20187:00 amRNSAstraZeneca:high level results of the ARCTIC trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.